How Is The Short Bowel Syndrome Market Expected To Grow At 14.4% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Short Bowel Syndrome Market Be Worth By 2029?
There has been a significant expansion in the market size for short bowel syndrome over the past few years. The market, which is projected to rise from $2.69 billion in 2024 to $3.08 billion in 2025, is anticipated to have a compound annual growth rate (CAGR) of 14.6%. Factors contributing to this growth during the historic period include heightened instances of gastrointestinal complications, escalated expenditures on healthcare and insurance coverage, advancements in the post-operative care of SBS, rise in the incidence of Crohn’s disease and other GI complications, and upgrades in parenteral nutrition formulations and application methods.
In the upcoming years, the short bowel syndrome market is anticipated to witness substantial growth, expanding to $5.29 billion in 2029 with a CAGR of 14.4%. The escalation during the forecast period can be credited to factors such as the increasing incidence of short bowel syndrome (SBS), the rising uptake of parenteral and enteral nutrition therapy, the development of clinical research and medicinal studies, escalating health care expenditure, and the growth in awareness and premature diagnosis of SBS. Key trends during the forecast period are expected to be improvements in intestinal rehabilitation treatments, advancements in small intestine transplant procedures, the utilization of telemedicine for managing SBS, technological progress in enteral feeding devices, and the incorporation of artificial intelligence in planning SBS treatment.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp
What External And Internal Drivers Are Influencing The Short Bowel Syndrome Market?
The anticipated ascent in the occurrence of gastrointestinal disorders is predicted to spur expansion of the short bowel syndrome industry. These disorders feature a range of issues influencing the digestive system, such as conditions affecting the stomach, intestines, liver and pancreas, which often lead to dysfunction in digestion and the absorption of nutrients. Unhealthy diet habits are primarily responsible for the rising occurrence of gastrointestinal diseases, often damaging gut health and promoting inflammation. This kind of diseases can lead to the onset of short bowel syndrome by necessitating the surgical elimination of damaged intestinal segments, thus reducing absorptive capabilities. For instance, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre in Canada reported in September 2023, that over 320,000 individuals in Canada had IBD, with a prevalence rate of 825 per 100,000. The rate is expected to rise annually by 2.44%, implying that by 2035, 1.1% of the population, or roughly 470,000 Canadians, may be living with IBD. Therefore, the escalating occurrence of gastrointestinal diseases promotes the growth of the short bowel syndrome market.
What Segmentation Insights Are Provided In The Short Bowel Syndrome Market Research?
The short bowel syndromemarket covered in this report is segmented –
1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine
2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis
3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant
4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels
Subsegments:
1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues
2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies
3) By Glutamine: Oral Glutamine; Intravenous Glutamine
Which Market Trends Are Expected To Define The Future Of The Short Bowel Syndrome Market?
The emphasis of leading corporations in the short bowel syndrome sector is on spurring innovative progress in medical studies, such as therapies for intestinal failure, to offer a sophisticated treatment alternative that bolsters patient outcomes grappling with gastrointestinal maladies. Intestinal failure, a grave condition, occurs when the small intestine fails to absorb adequate nutrients, fluids, and electrolytes, thereby impeding proper hydration and nutrition. For example, American healthcare firm Ironwood Pharmaceuticals, Inc., revealed fresh data from tests assessing apraglutide’s impact on adults with short bowel syndrome and intestinal failure (SBS-IF) in May 2024. As an up-and-coming GLP-2 analog, apraglutide showed the potential to augment intestinal absorption and minimize dependence on parenteral support. The results emphasize the drug’s effectiveness, safety, and lasting benefits, mirroring Ironwood’s dedication to the creation of groundbreaking therapies for gastrointestinal issues.
Who Are The Leading Companies Driving The Short Bowel Syndrome Market?
Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc. , Adocia SAS, EnteraBio Ltd, GLyPharma Therapeutic Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report
Which Geographic Regions Are Creating Strong Demand In The Short Bowel Syndrome Market?
North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp
Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2025, By The Business Research Company
Inflammatory Bowel Disease Treatment Global Market Report 2025
Irritable Bowel Syndrome Ibs Treatment Global Market Report 2025
Cough Hypersensitivity Syndrome Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
